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R ADIOLABELED
CYCLIC RGD (ARGININE-GLYCINE-ASPARTIC ACID) PEPTIDES represent a new class of radiotracers that target the integrin a v b 3 expressed on tumor cells and activated endothelial cells of the tumor neovasculature. [1] [2] [3] [4] [5] [6] [7] [8] [9] Noninvasive measurement of integrin a v b 3 expression is highly desirable for patient selection before antiangiogenic treatment and for more effective monitoring of therapeutic efficacy in integrin a v b 3 -positive cancer patients. [10] [11] [12] Over the last several years, many multimeric cyclic RGD peptides, such as E[c(RGDfK)] 2 (RGD 2 ) and E{E[c(RGDfK)] 2 } 2 (RGD 4 ), have been used to maximize integrin a v b 3 binding affinity and radiotracer tumor uptake. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] It has been demonstrated that radiolabeled ( 99m Tc, 18 F, 64 Cu, 68 Ga, and 111 In) multimeric cyclic RGD peptides have better tumortargeting capability, as evidenced by their higher tumor uptake, with longer tumor retention time than their monomeric counterparts. Recently, we reported a series of 99m Tc-labeled cyclic RGD dimers, examples of which are shown in Figure 1 ( 99m Tc-3P-RGD 2 : 3P-RGD 2 5 PEG 4 -E[PEG 4 -c(RGDfK)] 2 , PEG 4 5 15-amino-4,7,10,13-tetraoxa-pentadecanoic acid; and 99m Tc-3G-RGD 2 , 3G-RGD 2 5 G 3 -E[G 3 -c(RGDfK)] 2 , G 3 5 Gly-Gly-Gly), as new radiotracers for tumor imaging in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts. 25, 26 The integrin a v b 3 binding assay showed that 3P-RGD 2 and 3G-RGD 2 are bivalent, as evidenced by their higher binding affinity than that of RGD 2 . It has been clearly demonstrated that the addition of PEG 4 and G 3 linkers is responsible for the improved tumor uptake of 99m Tc-3P-RGD 2 and 99m Tc-3G-RGD 2 owing to their bivalency in binding to integrin a v b 3 and their faster clearance kinetics from the liver and kidneys. Similar results were obtained for other radiotracers, [27] [28] [29] [30] [31] such as 99m TcO(MAG 2 -3G-RGD 2 ) (see Figure 1 : MAG 2 5 mercaptoacetylglycylglycyl), 30 99m TcO(MAG 2 -3P-RGD 2 ), 31 64 Cu(DOTA-3P-RGD 2 ) (DOTA 5 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid), and 64 Cu(DOTA-3G-RGD 2 ). 27 99m Tc-3P-RGD 2 has been selected as a candidate for clinical evaluations because of its high tumor uptake, long tumor retention time, and high metabolic stability in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts. 32 It is well established that integrin a v b 3 is highly expressed on tumor cells and activated endothelial cells of the tumor neovasculature. [33] [34] [35] [36] [37] [38] [39] Although a good correlation was reported, the integrin a v b 3 expressed on the neovasculature was completely ignored.
In this study, we evaluated 99m Tc-3P-RGD 2 for its ability to monitor integrin a v b 3 expression levels in five different xenografted tumor-bearing animal models (U87MG glioma, MDA-MB-435 breast cancer, A549 lung cancer, HT29 colon cancer, and PC-3 prostate cancer). We were interested in these five human tumor cell lines because they have different levels of integrin a v b 3 expression. 46 For comparison purposes, 99m Tc-3G-RGD 2 and 99m TcO(MAG 2 -3G-RGD 2 ) were evaluated in the same animal models. The main objective of this study was to establish the relationship between tumor uptake and integrin a v b 3 expression levels regardless of the radiotracer's identity and to characterize the integrin a v b 3 expression levels on both tumor cells and activated endothelial cells of tumor neovasculature.
Experimental

Materials and Methods
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 99m Tc-3P-RGD 2 , 99m Tc-3G-RGD 2 , and 99m TcO (MAG 2 -3G-RGD 2 ) were prepared according to methods described in the literature. 25 4 OAc buffer, pH 5 5.0) and 10% solvent B (acetonitrile) at 0 to 2 minutes, followed by a gradient mobile phase going from 10% solvent B at 2 minutes to 15% solvent B at 5 minutes and 20% solvent B at 20 minutes.
Animal Model
Biodistribution and imaging studies were performed in compliance with the National Institutes of Health animal experimentation guidelines. 47 The protocol was approved by the Purdue University Animal Care and Use Committee. All human tumor cell lines (U87MG, MDA-MB-435, A549, HT29, and PC-3) were obtained from American Type Culture Collection (ATCC, Manassas, VA). The U87MG human glioma cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich) with Earle's Balanced Salt Solution (nonessential amino acids sodium pyruvate; Invitrogen, Carlsbad, CA) (ATCC). PC-3 and A549 cancer cells were cultured in F-12 medium (GIBCO, Grand Island, NY). MDA-MB-435 and HT29 cancer cells were grown in RPMI 1640 medium with L-glutamine (GIBCO). All tumor cell lines were supplemented with 10% fetal bovine serum (FBS, ATCC) and 1% penicillin and streptomycin (GIBCO) solution and grown at 37uC in a humidified atmosphere of 5% CO 2 in air. Cells were grown as monolayers and were harvested or split when they reached 90% confluence to maintain exponential growth. Female athymic nu/nu mice were purchased from Harlan Laboratories (Indianapolis, IN) at 4 to 5 weeks of age and were subcutaneously implanted with 5 3 10 6 tumor cells in 0.1 mL of saline into mammary fat pads (MDA-MB-435) or shoulder flanks (U87MG, A549, HT29, and PC-3). All procedures were performed in a laminar flow cabinet using aseptic techniques. Four to 6 weeks after inoculation, the tumor size was 0.1 to 0.5 g, and the animals were used for biodistribution and imaging studies.
Biodistribution Protocol
Three female athymic nude mice (weight 20-25 g) bearing the U87MG, MDA-MB-435, A549, HT29, or PC-3 tumor xenografts were administered with the 99m Tc radiotracer (<2.5 mCi per mouse in 0.1 mL saline) via tail vein. Animals were sacrificed at 60 minutes postinjection. Tumors were excised, dried with absorbent tissue, weighed, and counted on a PerkinElmer Wizard -1480 automatic gamma-counter (Shelton, CT). This experiment was performed twice. The tumor uptake was calculated as a percentage of the injected dose per gram of wet tissue mass (%ID/g), and the biodistribution data were presented as the mean plus the standard deviation from six tumorbearing animals in each group.
Planar Imaging
Planar imaging was performed using the athymic nude mice (n 5 3) bearing U87MG, MDA-MB-435, A549, HT29, or PC-3 tumor xenografts. Each animal was administered with <300 mCi of 99m Tc radiotracer in 0.1 mL saline via tail vein injection. Animals were anesthetized with intraperitoneal injection of ketamine (80 mg/kg) and xylazine (12 mg/kg) and were then placed supine on a custom-made single-head mini gamma camera (Diagnostic Services Inc., Middlesex, NJ) equipped with a parallel-hole, low-energy, and highresolution collimator. Anterior images were acquired at 15, 30, 60, and 120 minutes postinjection and stored digitally in a 128 3 128 matrix. The acquisition count limits were set at 300 K. After completion of imaging, animals were sacrificed by sodium pentobarbital overdose (<200 mg/kg). The whole-body planar images were selected and reported without filtration.
Cultured Primary Tumor Cells
Tumor tissues (U87MG, MDA-MB-435, A549, HT29, or PC-3) were excised from the tumor-bearing mice and were immersed in a growth medium immediately after gamma counting. The tumor tissues were rinsed twice with the Hank's solution and dissected into small pieces with razor blades. Small tumor pieces were digested with 0.25% trypsin (1 mM ethylenediaminetetraacetic acid [EDTA], without Ca 2+ and Mg 2+ ) solution at 37uC for 30 minutes, followed by vigorous pipeting and filtration through a 40 mm mesh nylon screen. After centrifugation at 1,000 rpm for 5 minutes, the pellet was resuspended in the culture medium and incubated at 37uC in a humidified atmosphere containing 5% CO 2 . The purity of tumor cells could reach <90% after two passages, and the third passage was used for immunostaining studies.
Cellular Immunostaining
For staining studies, the primary tumor cells (U87MG, MDA-MB-435, A549, HT29, and PC-3) were seeded into eight-well chamber slides. Cells were allowed to attach and spread for . 24 hours. The tumor cells were fixed in 220 u C methanol for 5 minutes and rinsed with phosphatebuffered saline (PBS). Cells were incubated in 5% bovine serum albumin for 30 minutes to block nonspecific binding and then were added to Alexa Fluor 488-conjugated mouse antihuman integrin a v b 3 monoclonal antibody LM609 (1:100; Millipore, Billerica, MA) for 1 hour at room temperature or incubated with rabbit antihuman and murine integrin b 3 antibody followed by incubation with Alexa Fluor 594-conjugated goat antirabbit IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). After washing with PBS, the slides were mounted with 49,6-diamidino-2-phenylindole (DAPI)-Fluoromount-G (SouthernBiotech, Birmingham, AL). The same procedure, except the primary antibody was replaced by PBS, served as the negative control. The same experiment was repeated three times independently. This procedure was also used for cellular fluorescent staining studies with the human U87MG, MDA-MB-435, A549, HT29, and PC-3 cell lines.
Tumor Tissue Immunohistochemistry
For tissue staining studies, the tumor tissues were harvested from the tumor-bearing mice and were immediately snap-frozen in the optical cutting temperature solution. Tumor tissues were then cut into slices (5 mm). After thorough drying at room temperature, the slides were fixed with ice-cold acetone for 10 minutes and dried in the air for 20 minutes at room temperature. The sections were blocked with 10% goat serum for 30 minutes at room temperature and then were incubated with the hamster anti-integrin b 3 antibody (1:100; BD Biosciences, San Jose, CA) and rat anti-CD31 antibody (1:100; BD Biosciences) for 1 hour at room temperature. After incubating with the Cy3-conjugated goat antihamster and fluorescein isothiocyanate (FITC)-conjugated goat antirat secondary antibodies (1:100; Jackson ImmunoResearch Inc., West Grove, PA) and washing with PBS, the fluorescence was visualized with a Nikon fluorescence microscope (Nikon Instruments, Melville, NY). Quantitative analysis of CD31 and the total b 3 expression levels was performed after immunostaining of the tumor tissues. All pictures were taken under 1003 magnification with the same exposure time. Brightness and contrast adjustments were made equally to all images. The average area of positively stained CD31 or b 3 on cryostat sections from at least 15 randomly selected fields in each group was calculated to assess the relative expression in the tumor tissues by National Institutes of Health ImageJ software (Bethesda, MD). Experiments were repeated three times independently. The fluorescent density was expressed as a percentage of the total area and presented as the mean 6 SD. The fluorescent density data were plotted against the radiotracer %ID/g uptake (radioactivity density).
Data and Statistical Analysis
Analysis of the expression of CD31 and total b 3 was derived from at least 15 different regions under 1003 magnification and expressed as mean 6 SD. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by the Newman-Keuls test for multiple comparisons. The level of significance was set at p , .05.
Results
Biodistribution
In this study, we used five animal models (U87MG, MDA-MB-435, A549, HT29, and PC-3) to compare the tumor uptake of three 99m Tc radiotracers. As illustrated in Figure 2 , TcO(MAG 2 -3G-RGD 2 ), respectively). Their uptake in the xenografted MDA-MB-435, A549, and HT29 tumors was moderate and comparable at 60 minutes postinjection within the experimental error. The tumor uptake of 99m Tc-3P-RGD 2 followed a trend: U87MG (11.2 6 1.97%ID/g) . MDA-MB-435 (6.1 6 0.79 %ID/g) < HT29 (7.3 6 1.78 %ID/g) < A549 (5.5 6 1.46 %ID/g) .. PC-3 (2.29 6 0.64 %ID/g). The same general trend (see Figure 2) was observed for 99m Tc-3G-RGD 2 and 99m TcO(MAG 2 -3G-RGD 2 ).
Planar Imaging
To further confirm the results from biodistribution studies, we obtained whole-body images of the athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, and PC-3 xenografts. Once again, the U87MG tumors had the highest activity accumulation with the best contrast ( Figure 3 ). PC-3 tumors were not clearly visualized owing to low tumor uptake. The MDA-MB-435, A549, and HT29 tumors were also clearly visible for all three 99m Tc radiotracers. The tumor-to-background (T/B) contrast was not as good as that in the glioma-bearing animal model, but it was much better than that in the PC-3 model. The radiotracer tumor uptake followed a general trend: U87MG . MDA-MB-435 < HT29 < A549 . PC-3.
Integrin a v b 3 Expression Levels on Tumor Cells
To understand differences in the radiotracer tumor uptake, the integrin a v b 3 expression patterns were examined in the cultured primary tumor cells extracted from tumor-bearing mice. It is known that b 3 attaches to a IIb in addition to a v . Given that a IIb b 3 is exclusively expressed on activated platelets, 48 ,49 staining of b 3 can correlate a v b 3 expression in cultured primary tumor cells. Figure 4 shows the results from cellular immunostaining studies. Apparently, the integrin a v b 3 expression levels followed the order of U87MG . MDA-MB-435 . A549 < HT29 . PC-3 (see Figure 4 , left) in the cultured primary tumor cells using LM609 antibody. A similar trend was seen with the antibody against the b 3 subunit (see Figure 4 , right). The same results were obtained for the human cell lines with LM609 and the antibody against the b 3 subunit ( Figure S1A ). Western blot data (see supplementary Figure S1B and Figure S2A ) further confirmed the results from immunostaining studies. In Western blot studies, the antibody detects the total integrin b 3 , including the 97, 110, and 130 kilodalton variants. 50 Integrin a v expression was also evaluated. In all cases, PC-3 tumor cells had the lowest a v expression level (see supplementary Figure S2A ). 99m Tc-3P-RGD 2 , 99m Tc-3G-RGD 2 , and 99m TcO(MAG 2 -3G-RGD 2 ) in athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, and PC-3 tumor xenografts (N 5 6) at 60 minutes postinjection. For each group, the 99m Tc radiotracer (<2.5 mCi in 0.1 mL saline) was administered via tail vein. The tumor uptake data are expressed as %ID/g 6 SD. *p , .05, significantly different from all the other groups; { p , .05, significantly different from the U87MG group; # p , .05, significantly different from the PC3 group.
Integrin a v b 3 Expression Levels on Tumor Tissue
Immunohistochemistry was performed to determine the total integrin b 3 expression levels on both the tumor cells and tumor neovasculature. CD31 was used as the endothelial biomarker to assess blood vessel density. Figure 5 illustrates the microscopic fluorescence images of the xenografted tumor tissues (U87MG, MDA-MB-435, A549, HT29, and PC-3) labeled with anti-integrin b 3 (red) or anti-CD31 (green) antibody. In the overlay pictures, the green color indicates the presence of blood vessels, the red color indicates the presence of integrin b 3 , and the yellow color indicates integrin b 3 expressed on neovasculature. Figure 6 shows the quantitative analysis of CD31 (see Figure 6A ) and b 3 (see Figure 6B ) for five different xenografted tumor tissues (U87MG, MDA-MB-435, A549, HT29, and PC-3). The total b 3 expression (tumor cells and neovasculature) was defined by the percentage of the Tc-Labeled Cyclic RGD Dimers for Tumor Imaging red-colored area over the total area in each slice of tumor tissue. Blood vessel density (CD31 expression level) was quantified by measuring the percentage of the greencolored area over the total area in each tumor section slide. We found that the integrin b 3 expression level was the highest in U87MG glioma tissues and the lowest in PC3 tumor tissues. The total integrin b 3 expression levels followed the trend U87MG . MDA-MB-435 < A549 < HT29 . PC-3 (see Figure 6B) , which is completely consistent with the ex vivo biodistribution data (see Figure 2) . These results were further confirmed by the results from Western blot analysis of the tumor tissues (see supplementary Figure S2b ). In contrast, the blood vessel density was very high in U87MG glioma and HT29 tumor tissues, whereas it was very low in PC-3 tumor tissues. The CD31 expression levels followed the order of U87MG < HT29 . MDA-MB-435 < A549 . PC-3 (see Figure 6A) .
Relationship between Tumor Uptake and Integrin b 3 Expression Levels Figure 7 illustrates the plots of tumor uptake (%ID/g: radioactivity density) for 99m Tc-3P-RGD 2 (top), 99m Tc-3G-RGD 2 (middle), and 99m TcO(MAG 2 -3G-RGD 2 ) (bottom) and the integrin b 3 expression levels (fluorescence density) in the xenografted U87MG, MDA-MB-435, A549, HT29, and PC-3 tumor tissues. Apparently, there is a linear relationship between the radiotracer %ID/g tumor uptake and the integrin b 3 expression levels, with R 2 being .95, .92, and 0.96, respectively.
Discussion
In this study, we evaluated 99m Tc-3P-RGD 2 , 99m Tc-3G-RGD 2 , and 99m TcO(MAG 2 -3G-RGD 2 ) as the integrin a v b 3 -targeted radiotracers in five different tumor-bearing animal models. Biodistribution data indicate that all three 99m Tc radiotracers have the highest uptake in U87MG glioma and the lowest uptake in PC-3 tumors. The radiotracer tumor uptake followed the general trend of U87MG . MDA-MB-435 < HT29 < A549 . PC-3 (see Figure 2) , which was further confirmed by planar imaging studies (see Figure 3) . It was also found that the cultured primary U87MG tumor cells and U87MG tumor tissues had the highest integrin a v b 3 expression, whereas the cultured primary PC-3 tumor cells and PC-3 tumor tissues had the lowest integrin a v b 3 expression (see Figure 4) . Western blot data (see supplementary Figure S2A ) are completely consistent with the results from immunostaining studies (see Figure 4) . The integrin a v b 3 levels on the cultured primary tumor cells followed the order of U87MG . MDA-MB-435 . HT29 < A549 . PC-3, which seems inconsistent with the general trend of the radiotracer tumor uptake (see Figure 2) . Thus, the contribution of the tumor neovasculature to the total integrin a v b 3 expression must be taken into account when comparing the radiotracer tumor uptake difference in various tumor-bearing animal models.
Integrin a v b 3 is overexpressed on both tumor cells and activated endothelial cells of the tumor neovasculature. [33] [34] [35] [36] [37] [38] [39] In this study, we found that the total integrin a v b 3 expression levels follow the order of U87MG . MDA-MB-435 < A549 < HT29 . PC-3 (see Figure 6B) . Even though the integrin a v b 3 expressed on the cultured primary HT29 colon cancer cells is not as high as that on MDA-MB-435 breast cancer cells (see Figure 3) , the higher blood vessel density (see Figure 6A ) in HT29 colon tumor tissues compared to that on the MDA-MB-435 breast tumor tissues might explain the similar radiotracer uptake in the xenografted MDA-MB-435 and HT29 tumors (see Figure 2) . On the basis of these results, we believe that the integrin a v b 3 expressed on both tumor cells and the neovasculature contributes to the tumor uptake of 99m Tc radiotracers. The linear relationship (see Figure 7) between the tumor uptake (%ID/g) and integrin a v b 3 density strongly suggests that 99m Tc-3P-RGD 2 , 99m Tc-3G-RGD 2 , and 99m TcO(MAG 2 -3G-RGD 2 ) are useful for noninvasive monitoring of integrin a v b 3 expression levels in cancer patients. This conclusion is completely consistent with the results from clinical studies with [ 18 F]galacto-RGD in cancer patients. [41] [42] [43] [44] [45] The ability to noninvasively quantify or estimate the integrin a v b 3 level provides new opportunities to select patients more appropriately for planning antiangiogenic treatment. [10] [11] [12] For example, if the patient shows significant tumor uptake of the radiotracer (PET or single-photon emission computed tomography [SPECT]) owing to high integrin a v b 3 expression, he or she would most likely be responsive to antiangiogenic treatment.
Conversely, if the patient shows very little radiotracer tumor uptake, indicating low integrin a v b 3 expression, antiangiogenic therapy would not be effective regardless of the amount of antiangiogenic drug administered to the cancer patient. The next question is how much of the contribution is from the tumor cells or the neovasculature. Based on the results from this study, we believe that the contribution from the tumor cell integrin a v b 3 depends largely on the Conversely, if the tumor has low integrin a v b 3 expression levels on tumor cells and neovasculature (eg, PC-3 prostate cancer), the radiotracer tumor uptake would be low. The xenografted U87MG and HT29 tumor tissues share a similar blood vessel density (see Figure 6A ), but the radiotracer tumor uptake (see Figure 2 ) in U87MG glioma is significantly higher than that in HT29 tumor owing to the higher integrin a v b 3 levels on U87MG glioma cells (see Figure 4) . Xenografted MDA-MB-435, A549, and HT29 tumors have similar integrin b 3 levels (see Figure 6B ) and share almost identical tumor uptake (see Figure 3) . The total integrin a v b 3 expression level is responsible for the a v b 3 -targeted radiotracer tumor uptake. It must be noted that not all blood vessels in tumor tissues express integrin a v b 3 . For example, many blood vessels have little expression of integrin b 3 in U87MG and HT29 tumor xenografts, as indicated by the green-colored area in the overlay images, whereas the majority of the blood vessels in the MDA-MB-435 and A549 tumor xenografts express integrin b 3 , as indicated by the presence of more yellowcolored area. Given that integrin b 3 is expressed in tumor microvessels, not mature large blood vessels, caution must be taken when correlating the radiotracer tumor uptake and blood vessel density.
It is important to note that the fluorescence distribution in the xenografted tumor tissues is not homogeneous. In many cases, the distribution pattern was significantly different on two tumors from the same animal or even in different areas of the same tumor tissue. In fact, the fluorescence distribution heterogeneity is characteristic of all five xenografted tumors (U87MG, MDA-MB-435, A549, HT29, and PC-3). This is also why we used the average area of positively stained b 3 and CD31 on cryostat sections from at least 15 randomly selected fields in each group to assess the fluorescence density in the tumor tissues. This may also explain why radiotracer tumor uptake values often have such a large standard deviation in biodistribution studies (see Figure 3) .
There are potential limitations to this study. First, the xenografted tumor models were established by subcutaneous injection of human tumor cells. Although the tumor-bearing animal models used in this study may not be representative of the microenvironment for the growth, invasion, and metastasis of human tumors, they are good enough for us to explore the relationship between radiotracer tumor uptake and integrin a v b 3 expression levels. Cellular staining data with LM609 suggest that cultured tumor primary cells are able to maintain many characteristics of human cancer cells. Second, quantification of the integrin a v b 3 heterodimer is extremely difficult because no Western blot techniques are currently available for the combined integrin a v b 3 subunits. In this study, we use ''fluorescent density'' from immunostaining studies to correlate the radiotracer tumor uptake (radioactivity density %ID/g) because quantification of absolute fluorescent intensity is very much operator dependent and subject to individual interpretation. Considering the ''uncontrolled recovery rate'' of the a v and b 3 subunits from the xenografted tumor tissues when lysing the tissues, the results of Western blot studies are used only as supplementary information. Third, tumors of different sizes might have different integrin a v b 3 expression patterns. The expression levels of integrin a v b 3 and blood vessel endothelial cell biomarker CD31 only represent the status under specific experimental conditions, which is restricted by multiple factors, including animal species and sex, inoculation location, tumor cell type and culture conditions, tumor growth time, and tumor size. For example, the PC-3 cell line is known for low expression of integrin a v b 3 . 51 However, the subcutaneous injection of PC-3 cells into the hindlimb of BALB/c nu/nu mice produced a higher level of angiogenesis. 52 Also, the higher level of integrin a v b 3 expression on activated endothelial cells in the xenografted tumor generated higher uptake of the imaging agent. 53 The slow progression and low density of the blood vessels in the PC-3 xenografted tumor shown in this study represent the outcome under particular experimental conditions (female athymic nude mice, subcutaneous injection in the shoulder flanks, etc.). We also found that PC-3 tumors grown in male mice had properties almost identical to those in female mice. Finally, further work needs to be done in cancer patients even though the linear relationship between tumor uptake (%ID/g) and integrin a v b 3 expression levels has been clearly established in the tumor-bearing animal models used in this study.
Conclusions
We evaluated 99m Tc-3P-RGD 2 for its ability to image integrin a v b 3 expression in xenografted U87MG, MDA-MB-435, A549, HT29, and PC-3 tumors. There are several significant findings from this study. First, the ex vivo biodistribution data indicate that 99m Tc-3P-RGD 2 has the highest uptake in U87MG glioma and the lowest uptake in PC-3 tumor. Its tumor uptake value followed the general trend: U87MG . MDA-MB-435 < A549 < HT29 . PC-3. The same general trend was observed for 99m Tc-3G-RGD 2 and 99m TcO(MAG 2 -3G-RGD 2 ). Cellular and tumor tissue immunostaining studies indicate that U87MG glioma cells and U87MG glioma tissues have the highest integrin a v b 3 expression levels, whereas the PC-3 cells and PC-3 tumor tissues have little integrin a v b 3 expression. The integrin a v b 3 expression levels on the cultured primary tumor cells followed the order of U87MG . MDA-MB-435 . HT29 < A549 . PC-3. The total integrin b 3 expression levels, as determined by tissue staining, followed the general trend: U87MG . MDA-MB-435 < A549 < HT29 . PC-3. There is a linear relationship between radiotracer %ID/g tumor uptake and integrin b 3 expression. Thus, we conclude that radiotracer tumor uptake is contributed by integrin a v b 3 Tc-Labeled Cyclic RGD Dimers for Tumor Imaging expressed on both tumor cells and activated endothelial cells of the tumor neovasculature. 99m Tc-3P-RGD 2 is an excellent candidate for clinical evaluations because of its high tumor uptake, long tumor retention time, high metabolic stability, and ability to monitor integrin a v b 3 expression in a noninvasive fashion.
